The FAUCI Act would impose new restrictions on senior federal health officials from the National Institutes of Health, Food and Drug Administration, and Centers for Disease Control and Prevention. The bill prohibits these top officials from serving on the boards of companies that develop or research drugs, biological products, or devices for eight years after leaving their government position, and bars them from profiting from such products if they were involved in approving related grant applications during their employment. Violations of the board service prohibition would carry penalties under existing law, while profiting from approved drugs or devices could result in fines up to $250,000 and imprisonment for one to five years. The bill also prevents current top officials from obtaining patents for drugs, biological products, or devices and requires existing officials and their spouses to disclose any patent ownership within 180 days of the law's enactment. The restrictions would apply to individuals leaving federal service after the bill's enactment, with a six-month compliance period for those who left before enactment.